Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat

Diabetologia

Volumn 55, Issue 4, 2012, Pages 1071-1080

  Futamura, M ^a   Yao, J ^b   Li, X ^b   Bergeron, R ^b   Tran, J L ^b   Zycband, E ^b   Woods, J ^b   Zhu, Y ^b   Shao, Q ^b   Maruki Uchida, H ^a   Goto Shimazaki, H ^a   Langdon, R B ^b   Erion, M D ^b   Eiki, J ^a   Zhou, Y P ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; Beta cell mass; Glucokinase activator; Insulin secretion; Islets of Langerhans; Sulfonylurea; Type 2 diabetes

Indexed keywords

(3 [2 HYDROXY 1 METHYLETHOXY] 5 [4 (METHYLSULFONYL) PHENOXY] N 1,3 THIAZOL 2 YL)BENZAMIDE; 6 ((4H 1,2,4 TRIAZOL 3 YL)THIO) 3 ((6 METHYLPYRIDIN 3 YL)THIO) N (1,2,4 THIADIAZOL 5 YL)PICOLINAMIDE; ANTIDIABETIC AGENT; CASPASE 3; CPD B; CPD C; GLIPIZIDE; GLUCAGON; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOSE; HYDROGEN PEROXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD SAMPLING; BODY MASS; CELL CULTURE; CELL DEATH; CELL LOSS; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DISEASE COURSE; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCOGEN ANALYSIS; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; SINGLE DRUG DOSE; ZUCKER DIABETIC FATTY RAT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATORS; GLUCOKINASE; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; RATS; RATS, ZUCKER; SULFONES; THIADIAZOLES;

EID: 84862826583     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2439-3     Document Type: Article

References (49)

1. Matschinsky FM, Magnuson MA, Zelent D et al (2006) The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55:1-12
2. Grimsby J, Sarabu R, Corbett WL et al (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370-373
3. Nakamura A, Terauchi Y, Ohyama S et al (2009) Impact of small-molecule glucokinase activator on glucose metabolism and β-cell mass. Endocrinology 150:1147-1154
4. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399-416
5. Sarabu R, Berthel SJ, Kester RF, Tilley JW (2011) Novel gluco-kinase activators: a patent review (2008-2010). Expert Opin Ther Pat 21:13-33
6. Davis EA, Cuesta-Muñoz A, Raoul M et al (1999) Mutants of glucokinase cause hypoglycaemia-and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 42: 1175-1186
7. Cuesta-Muñoz AL, Huopio H, Otonkoski T et al (2004) Severe persistent hyperinsulinemic hypoglycemia due to a de novo glu-cokinase mutation. Diabetes 53:2164-2168
8. Osbak KK, Colclough K, Saint-Martin C et al (2009) Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsuli-nemic hypoglycemia. Hum Mutat 30:1512-1526
9. Hussain K (2010) Mutations in pancreatic β-cell glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus. Rev Endocr Metab Disord 11:179-183
10. Kassem S, Bhandari S, Rodríguez-Bada P et al (2010) Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med 362:1348-1350
11. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12:429-438
12. Coope GJ, Atkinson AM, Allott C et al (2006) Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 149:328-335
13. Futamura M, Hosaka H, Kadotani A et al (2006) An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 281:37668-37674
14. Fyfe MC, White JR, Taylor A et al (2007) Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulino-tropic actions. Diabetologia 50:1277-1287
15. Ohyama S, Takano H, Iino T et al (2010) A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. Eur J Pharmacol 640:250-256
16. Bonadonna RC, Heise T, Arbet-Engels C et al (2010) Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95:5028-5036
17. Meininger GE, Scott R, Alba M et al (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34:2560-2566
18. Bell GI, Polonsky KS (2001) Diabetes mellitus and genetically programmed defects in β-cell function. Nature 414:788-791
19. Rhodes CJ (2005) Type 2 diabetes\a matter of β-cell life and death? Science 307:380-384
20. Newsholme P, Haber EP, Hirabara SM et al (2007) Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 583:9-24
21. Drews G, Krippeit-Drews P, Düfer M (2010) Oxidative stress and beta-cell dysfunction. Pflugers Arch 460:703-718
22. Danial NN, Gramm CF, Scorrano L et al (2003) BAD and gluco-kinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424:952-956
23. Kim WH, Lee JW, Suh YH et al (2005) Exposure to chronic high glucose induces β-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic β-cells. Diabetes 54:2602-2611
24. Terauchi Y, Takamoto I, Kubota N et al (2007) Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117:246-257
25. Wei P, Shi M, Barnum S, Cho H, Carlson T, Fraser JD (2009) Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells. Diabetologia 52:2142-2150
26. Halban PA, German MS, Kahn SE, Weir GC (2010) Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab 95:1034-1043
27. Porat S, Weinberg-Corem N, Tornovsky-Babaey S et al (2011) Control of pancreatic β cell regeneration by glucose metabolism. Cell Metab 13:440-449
28. Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 95:2498-2502
29. Pick A, Clark J, Kubstrup C et al (1998) Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358-364
30. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP (1999) Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 96:10857-10862
31. Unger RH, Orci L (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 15:312-321
32. Iino T, Hashimoto N, Sasaki K et al (2009) Structure-activity relationships of 3, 5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorg Med Chem 17:3800-3809
33. Miyazaki J, Araki K, Yamato E et al (1990) Establishment of a pancreatic β cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127:126-132
34. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K channel-dependent and-independent glucose-stimulated insulin secretion. Diabetes 49:424-430
35. Walaas O, Walaas E (1950) Effect of epinephrine on rat diaphragm. J Biol Chem 187:769-776
36. Zhou YP, Marlen K, Palma JF et al (2003) Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? J Biol Chem 278:51316-51323
37. Bonner-Weir S, Weir GC (2005) New sources of pancreatic β-cells. Nat Biotechnol 23:857-861
38. Butler PC, Meier JJ, Butler AE, Bhushan A (2007) The replication of β cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 3:758-768
39. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger RH (1982) Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 3:694-700
40. Clark A, Wells CA, Buley ID et al (1988) Islet amyloid, increased A-cells, reduced B cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159
41. Yoon KH, Ko SH, Cho JH (2003) Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300-2308
42. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110
43. Newsholme P, Morgan D, Rebelato E et al (2009) Insights into the critical role of NADPH oxidase(s) in the normal and dysregulated pancreatic beta cell. Diabetologia 52:2489-2498
44. Poitout V, Robertson RP (2008) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29:351-366
45. Lenzen S, Drinkgern J, Tiedge M (1996) Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 20:463-466
46. Thorrez L, Laudadio I, van Deun K et al (2011) Tissue-specific disallowance of housekeeping genes: the other face of cell differentiation. Genome Res 21:95-105
47. Burkart V, Wang ZQ, Radons J et al (1999) Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 5:314-319
48. Chang I, Cho N, Koh JY, Lee MS (2003) Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes. Diabetologia 46:1220-1227
49. Bebernitz GR, Beaulieu V, Dale BA et al (2009) Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 52:6142-6152